Actuate Therapeutics, Inc. (ACTU)
0.9812
-0.01
(-1.41%)
USD |
NASDAQ |
Sep 18, 16:00
0.98
0.00 (0.00%)
After-Hours: 07:01
Actuate Therapeutics Net Income (Quarterly) : -4.867M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.867M |
| March 31, 2026 | -5.626M |
| December 31, 2025 | -4.554M |
| September 30, 2025 | -5.408M |
| June 30, 2025 | -5.949M |
| March 31, 2025 | -6.317M |
| December 31, 2024 | -6.446M |
| Date | Value |
|---|---|
| September 30, 2024 | -5.971M |
| June 30, 2024 | -6.572M |
| March 31, 2024 | -8.296M |
| December 31, 2023 | -7.612M |
| September 30, 2023 | -6.338M |
| June 30, 2023 | -5.524M |
| March 31, 2023 | -5.270M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.867M |
| EPS Diluted (Quarterly) | -0.2039 |
| Enterprise Value | 19.54M |
| Earnings Yield | -90.86% |
| Normalized Earnings Yield | -90.86 |